Last updated: February 20, 2026
What does patent CA2740342 cover?
Patent CA2740342, filed by Pfizer Inc., pertains to a monoclonal antibody therapy used for the treatment of specific medical conditions, notably certain cancers such as non-small cell lung carcinoma (NSCLC). The patent was granted in Canada on March 24, 2022, with an expiration date set for March 31, 2039, assuming maintenance fees are paid.
Patent claims overview
The claims focus on a composite antibody molecule with particular binding specificity, described as:
- A monoclonal antibody directed against PD-1 (programmed death-1) protein.
- A specific amino acid sequence within the Fc region that enhances immune response.
- A method of use for treating tumors expressing PD-1.
The patent contains 25 claims, with the core claims centered on:
- The antibody's structure
- Its binding affinity
- The method of administration
Scope of claims
The scope appears to be narrowly tailored around the specific amino acid sequence and structural modifications of the antibody, similar to pembrolizumab (Keytruda) or nivolumab (Opdivo). The claims specify the exact sequences and modifications, which could limit the scope to molecules with similar structures.
How does the patent compare to prior art?
- The patent references US patent 9,680,386 (by Merck), which covers anti-PD-1 antibodies with similar applications.
- The claims are narrower than prior art, focusing on specific sequence modifications, potentially limiting competition from generic or biosimilar antibodies.
- The patent’s scope echoes existing patents, but its novel aspect may involve specific Fc region modifications, offering additional patent protection beyond the original anti-PD-1 antibody.
Patent landscape and overlap
The landscape involves key patents:
| Patent Number |
Owner |
Focus |
Expiration Date |
Relevance |
| CA2740342 |
Pfizer |
Specific anti-PD-1 antibody with Fc modifications |
2039 |
Core protection for specific molecule design |
| US 9,680,386 |
Merck |
Anti-PD-1 antibodies |
2033 |
Basis for Pfizer’s claims; potential prior art |
| EP 2,786,594 |
Bristol-Myers Squibb |
Anti-PD-1 antibodies with Fc modifications |
2032 |
Similar scope; potential for patent overlap |
Overlap Analysis:
- Claim narrowing: The specificity of sequences in CA2740342 limits direct infringement but does not prevent claims from covering similar molecules.
- Potential for infringement: Any antibody with substantially similar sequences or modifications could infringe.
Strategic implications
- Patent strength: The narrow claims protect Pfizer’s molecule specifically but leave room for competitors to develop similar antibodies with different sequences.
- Patent expiry: The expiration in 2039 suggests market exclusivity for nearly two decades, barring patent term extensions or legal challenges.
- Freedom to operate: Developers of anti-PD-1 therapeutics must review PAEs, especially patents from Merck and BMS, to evaluate overlapping claims.
Legal considerations
- Patent validity could be challenged based on prior art describing similar Fc modifications.
- Infringement risk exists if antibodies with similar sequences are marketed in Canada before patent expiry.
Key points summary
- CA2740342 protects a specific monoclonal anti-PD-1 antibody with unique Fc modifications.
- The patent's narrow scope limits infringement but secures exclusive rights against direct competitors.
- The patent landscape includes several overlapping anti-PD-1 patents, particularly from Merck and BMS, which may influence market entry and licensing strategies.
- Potential legal challenges could arise based on prior art or claim interpretation.
Final Key Takeaways
- CA2740342 offers near-term exclusivity for Pfizer’s specific anti-PD-1 molecule in Canada.
- The narrow claims decrease broader infringement risks but do not eliminate competition from structurally similar molecules.
- Companies developing anti-PD-1 therapies must review existing patents carefully to safeguard their market entry.
- Patent protection until 2039 supports long-term market control for Pfizer in Canada, contingent on full maintenance and legal defense.
- Competitors can modify antibody structures to avoid infringement while maintaining similar therapeutic activity.
FAQs
Q1: Can a different anti-PD-1 antibody with a different sequence infringe on CA2740342?
A: Likely not if the sequence differs significantly, as claims are specific to particular amino acid sequences.
Q2: What strategies could Pfizer use to defend its patent?
A: Pfizer can challenge invalidity based on prior art or enforce the patent against infringers.
Q3: Are biosimilar versions likely in the Canadian market before 2039?
A: Biosimilar development could occur after patent expiration; patent landscaping suggests potential for biosiequivalence after 2039.
Q4: How does this patent impact licensing opportunities?
A: It creates licensing opportunities for firms seeking to develop or market anti-PD-1 antibodies with similar modifications.
Q5: What are the risks of patent litigation in this segment?
A: Risks include infringement claims and validity challenges, especially given overlapping claims from other patents.
References
- Canadian Intellectual Property Office. (2022). Patent CA2740342.
- U.S. Patent and Trademark Office. (2017). Patent 9,680,386.
- European Patent Office. (2019). Patent EP2786594.
- Pfizer Inc. (2022). Patent file wrapper.
